Login / Signup

Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase.

Leah S TorrieDavid A RobinsonMichael G ThomasJudith V HobrathSharon M ShepherdJohn M PostEun-Jung KoRafael Alves FerreiraClaire J MackenzieKarolina WrobelDarren P EdwardsIan H GilbertDavid W GrayAlan H FairlambManu De Rycker
Published in: ACS infectious diseases (2020)
Methionyl-tRNA synthetase (MetRS) is a chemically validated drug target in kinetoplastid parasites Trypanosoma brucei and Leishmania donovani. To date, all kinetoplastid MetRS inhibitors described bind in a similar way to an expanded methionine pocket and an adjacent, auxiliary pocket. In the current study, we have identified a structurally novel class of inhibitors containing a 4,6-diamino-substituted pyrazolopyrimidine core (the MetRS02 series). Crystallographic studies revealed that MetRS02 compounds bind to an allosteric pocket in L. major MetRS not previously described, and enzymatic studies demonstrated a noncompetitive mode of inhibition. Homology modeling of the Trypanosoma cruzi MetRS enzyme revealed key differences in the allosteric pocket between the T. cruzi and Leishmania enzymes. These provide a likely explanation for the lower MetRS02 potencies that we observed for the T. cruzi enzyme compared to the Leishmania enzyme. The identification of a new series of MetRS inhibitors and the discovery of a new binding site in kinetoplastid MetRS enzymes provide a novel strategy in the search for new therapeutics for kinetoplastid diseases.
Keyphrases
  • small molecule
  • trypanosoma cruzi
  • high throughput
  • molecular docking
  • emergency department
  • hydrogen peroxide
  • electronic health record